Induction therapy with obinutuzumab plus bendamustine or obinutuzumab plus CHOP, followed by obinutuzumab maintenance, is associated with tolerable safety and promising efficacy in patients with follicular lymphoma.

**GAUDI was a non-randomized trial**
Untreated patients with follicular lymphoma allocated to one of the two induction chemotherapy backbones on a per-center basis.

**Induction therapy**
- obinutuzumab plus bendamustine
  - 4-6 cycles every 4 weeks
  - Completed by 90% patients

**Maintenance therapy**
- Patients with end-of-treatment response
- obinutuzumab
  - every 3 months for 2 years or until disease progression
  - Completed by 81% patients

**Progression free survival rate at 36 months**
- 90%

**Induction therapy with obinutuzumab plus CHOP**
- 6-8 cycles every 3 weeks
  - Completed by 95% patients

**Maintenance therapy**
- obinutuzumab
  - every 3 months for 2 years or until disease progression
  - Completed by 72% patients

**Progression free survival rate at 36 months**
- 84%

*Grigg et al., Haematologica, 2017*